Elicera Therapeutics AB (ELIC) AI Stock Analysis

• Market Cap: €287.33M
• Dividend Yield: N/A
• Average Volume (3M): 202.70K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.88
• Revenue Growth: N/A
• EPS Growth: 53.88%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 48,535,545
• 10 Day Avg. Volume: 173,167
• 30 Day Avg. Volume: 202,700
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

Elicera Therapeutics AB's stock shows significant financial challenges, particularly in profitability and cash flow, which are major risks for investors. While the technical analysis indicates positive momentum, the valuation metrics reveal concerns about future profitability and shareholder returns. The overall score reflects these mixed factors, with financial performance being a major area of concern.

Elicera Therapeutics AB Business Overview & Revenue Model

Company Description

Elicera Therapeutics AB (ELIC) is a biotechnology company based in Sweden, specializing in the development of immuno-oncology treatments. The company focuses on creating next-generation CAR T-cell therapies and oncolytic viruses, with the aim of harnessing the body's immune system to combat cancer. Elicera's core products are centered around its proprietary platform technologies, designed to enhance the efficacy and safety of immunotherapies across various cancer indications.

How the Company Makes Money

Elicera Therapeutics AB generates revenue primarily through research and development collaborations, licensing agreements, and potential milestone payments related to its proprietary technologies and therapeutic candidates. The company may also seek grants and funding from governmental or non-governmental entities to support its research initiatives. Elicera's revenue model is likely driven by strategic partnerships with larger pharmaceutical companies, which can provide upfront payments, research funding, and royalties on future sales if the therapies reach commercialization. Additionally, successful clinical trials and regulatory approvals could open avenues for direct sales or additional licensing deals.

Elicera Therapeutics AB Financial Statement Overview

Summary

Elicera Therapeutics AB faces significant challenges with profitability and cash generation, demonstrated by consistent losses and negative cash flow. Despite a strong equity position with no debt, the declining revenue and cash flow figures point to potential risks in financial sustainability.

Income Statement

Elicera Therapeutics AB shows a volatile revenue trend with a decline in revenue from 2023 to 2024. The company operates at a significant loss, demonstrated by negative EBIT and net income margins, indicating challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with no debt, reflected in a low debt-to-equity ratio. However, declining equity and total assets indicate potential challenges in sustaining financial stability.

Cash Flow

Negative operating and free cash flow highlight cash management challenges. The significant drop in free cash flow growth from 2023 to 2024 raises concerns about the company's ability to generate cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44M	7.13M	11.23M	1.28M	587.00	0.00
Gross Profit	1.20M	7.13M	11.22M	1.27M	-11.19K	-11.78K
EBITDA	-18.78M	-16.82M	-17.09M	-19.43M	-13.11M	-2.82M
Net Income	-18.75M	-16.11M	-16.40M	-19.52M	-13.12M	-2.82M
Balance Sheet
Total Assets	46.38M	27.56M	30.18M	46.31M	54.74M	12.59M
Cash, Cash Equivalents and Short-Term Investments	45.65M	26.40M	29.38M	43.82M	52.39M	11.56M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	13.63M	6.79M	13.78M	13.51M	2.50M	2.35M
Stockholders Equity	32.75M	20.77M	16.40M	32.80M	52.24M	10.24M
Cash Flow
Free Cash Flow	-14.94M	-23.46M	-14.92M	-8.57M	-14.29M	-964.13K
Operating Cash Flow	-14.94M	-23.46M	-14.92M	-8.57M	-14.29M	-905.25K
Investing Cash Flow	1.00K	0.00	483.17K	0.00	-1.00K	-8.88K
Financing Cash Flow	19.89M	20.48M	0.00	0.00	55.12M	12.45M

Elicera Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ELIC, the sentiment is Negative. The current price of 5.41 is below the 20-day moving average (MA) of 6.53, below the 50-day MA of 6.13, and above the 200-day MA of 4.11, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 34.35 is Neutral, neither overbought nor oversold. The STOCH value of 11.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ELIC.

Elicera Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	44.95M	-1.00	0.00%	8.16%	-94.12%	-25.83%
ELIC	47 Neutral	€287.33M	―	-56.75%	―	―	53.88%
ATORX	39 Underperform	140.09M	>-0.01	0.00%	―	-5.46%	0.00%
BIOSGN	34 Underperform	111.54M	-3.89	0.00%	―	0.00%	65.16%
ACTI	32 Underperform	197.07M	-3.55	0.00%	―	0.00%	27.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%